Scientists are reporting a test which can predict which patients are most at risk
from aggressive prostate cancer, and whether they suffer an increased chance of treatment failure.
«Scientists report genetic test to help predict men at most risk
from aggressive prostate cancer.»
Not exact matches
In the group of patients with
aggressive, or high risk,
prostate cancer, the average number of days
from diagnosis to surgery or radiation treatment was 96 days for Caucasian patients, and 105 days for African American patients.
Dr Hayley Luxton, lead researcher
from the Molecular Diagnostics and Therapeutics Laboratory at University College London, said: «Using antibodies mounted with a toxic payload, we can exploit the fact that
aggressive prostate cancer cells have more NAALADL2.
A new population - based study
from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five - year period was not associated with an increased risk of
aggressive prostate cancer.
The researchers are now further investigating the possibility of using this approach on other
cancers, including
prostate cancer, where it could be used to distinguish more
aggressive tumors
from those that grow much more slowly, Bhatia says.
In addition, research continues to uncover new clues to identify which men are at highest risk of
aggressive prostate cancer and could most benefit
from screening and treatment.
Since most men with
prostate cancer have indolent (non-
aggressive) disease for which conservative therapy or surveillance would be appropriate treatment, the clinical challenge is not only how to identify those with
prostate cancer, but also how to distinguish those who would benefit
from surgical or other
aggressive treatment
from those who would not.
Furthermore, they found that D4A is more effective than abiraterone at killing
aggressive prostate cancer cells, suggesting that some patients may benefit
from direct treatment with D4A.
Men with
aggressive prostate cancer that has stopped responding to conventional treatment could potentially benefit
from a new class of
cancer drug designed to overcome drug resistance, a new study suggests.
Professor Ros Eeles
from the Institute of
Cancer Research and The Royal Marsden, who co-leads the prostate cancer ICGC study with Professor Colin Cooper from the ICR and Professors David Neal and Douglas Easton from The University of Cambridge, said: «One of the major challenges in treating prostate cancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop qu
Cancer Research and The Royal Marsden, who co-leads the
prostate cancer ICGC study with Professor Colin Cooper from the ICR and Professors David Neal and Douglas Easton from The University of Cambridge, said: «One of the major challenges in treating prostate cancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop qu
cancer ICGC study with Professor Colin Cooper
from the ICR and Professors David Neal and Douglas Easton
from The University of Cambridge, said: «One of the major challenges in treating
prostate cancer is determining who needs aggressive treatment — some are slow growing and will never need treatment whilst others will develop qu
cancer is determining who needs
aggressive treatment — some are slow growing and will never need treatment whilst others will develop quickly.
Newly published research
from Fred Hutch shows black men may be at heightened risk not only of developing
prostate cancer but also of having a more
aggressive form at a younger age.
In a report published in the New England Journal of Medicine, scientists say that a panel of 20 genes can distinguish the more common localized
prostate cancer that grows slowly and rarely spreads
from the more
aggressive type that can spread quickly.
The findings also hint that in coming years, it may be possible to use the panel not just among men with advanced disease but to distinguish between men who develop the slower growing type of
prostate cancer from the more
aggressive type.
But then a friend was diagnosed with a very
aggressive form of
prostate cancer and I got involved in helping rehab his pelvic floor through what I knew
from teaching women.